BACKGROUND: The primary goal of this trial was to evaluate the confirmed response rate of temsirolimus (CCI-779), a mammalian target of rapamycin in patients with advanced soft tissue sarcomas (STS). METHODS: Patients ≥18 years with measurable advanced STS, no prior chemotherapy for metastatic disease (adjuvant and neoadjuvant chemotherapy allowed), adequate organ function, and performance status of ≤2 were eligible. After premedication with an antihistamine, CCI-779 was given intravenously at 25 mg over 30 minutes on Days 1, 8, 15, and 22, repeated every 4 weeks. The primary endpoint was confirmed response rate per Response Evaluation Criteria in Solid Tumors. RESULTS: Between June 2004 and November 2005, a total of 41 patients were enrolled and began treatment; 40 patients are evaluable for response and adverse events. The median age was 62 years (range, 28-72 years) with 56% women. Eighty percent had high-grade STS, and 22% had prior adjuvant chemotherapy. There were 2 patients (5%; 95% confidence interval [CI], 1-17) (undifferentiated fibrosarcoma and uterine leiomyosarcoma) who achieved a confirmed partial response lasting 3 and 17 months, respectively. Thirty-nine (95%) patients have progressed, with a median time to progression of 2.0 months (95% CI, 1.8-3.5). The median overall survival was 7.6 months (95% CI, 6.1-15.9). Forty-three percent experienced grade 3+ adverse events that were possibly related to therapy. CONCLUSIONS: Temsirolimus in this patient population of STS had limited clinical activity and had moderate toxicities.
BACKGROUND: The primary goal of this trial was to evaluate the confirmed response rate of temsirolimus (CCI-779), a mammalian target of rapamycin in patients with advanced soft tissue sarcomas (STS). METHODS:Patients ≥18 years with measurable advanced STS, no prior chemotherapy for metastatic disease (adjuvant and neoadjuvant chemotherapy allowed), adequate organ function, and performance status of ≤2 were eligible. After premedication with an antihistamine, CCI-779 was given intravenously at 25 mg over 30 minutes on Days 1, 8, 15, and 22, repeated every 4 weeks. The primary endpoint was confirmed response rate per Response Evaluation Criteria in Solid Tumors. RESULTS: Between June 2004 and November 2005, a total of 41 patients were enrolled and began treatment; 40 patients are evaluable for response and adverse events. The median age was 62 years (range, 28-72 years) with 56% women. Eighty percent had high-grade STS, and 22% had prior adjuvant chemotherapy. There were 2 patients (5%; 95% confidence interval [CI], 1-17) (undifferentiated fibrosarcoma and uterine leiomyosarcoma) who achieved a confirmed partial response lasting 3 and 17 months, respectively. Thirty-nine (95%) patients have progressed, with a median time to progression of 2.0 months (95% CI, 1.8-3.5). The median overall survival was 7.6 months (95% CI, 6.1-15.9). Forty-three percent experienced grade 3+ adverse events that were possibly related to therapy. CONCLUSIONS:Temsirolimus in this patient population of STS had limited clinical activity and had moderate toxicities.
Authors: Robert J Motzer; Gary R Hudes; Brendan D Curti; David F McDermott; Bernard J Escudier; Sylvie Negrier; Brigitte Duclos; Laurence Moore; Timothy O'Toole; Joseph P Boni; Janice P Dutcher Journal: J Clin Oncol Date: 2007-09-01 Impact factor: 44.544
Authors: Joan Maurel; Antonio López-Pousa; Ramón de Las Peñas; Joaquín Fra; Javier Martín; Josefina Cruz; Antonio Casado; Andrés Poveda; Javier Martínez-Trufero; Carmen Balañá; María Auxiliadora Gómez; Ricardo Cubedo; Oscar Gallego; Belen Rubio-Viqueira; Jordi Rubió; Raquel Andrés; Isabel Sevilla; Juan Jose de la Cruz; Xavier García Del Muro; Jose María Buesa Journal: J Clin Oncol Date: 2009-03-09 Impact factor: 44.544
Authors: Charles D Blanke; Cathryn Rankin; George D Demetri; Christopher W Ryan; Margaret von Mehren; Robert S Benjamin; A Kevin Raymond; Vivien H C Bramwell; Laurence H Baker; Robert G Maki; Michael Tanaka; J Randolph Hecht; Michael C Heinrich; Christopher D M Fletcher; John J Crowley; Ernest C Borden Journal: J Clin Oncol Date: 2008-02-01 Impact factor: 44.544
Authors: Alan L Ho; Shyamprasad Deraje Vasudeva; Marick Laé; Tsuyoshi Saito; Violetta Barbashina; Cristina R Antonescu; Marc Ladanyi; Gary K Schwartz Journal: Cancer Res Date: 2012-07-10 Impact factor: 12.701
Authors: Nicolas J Llosa; Kenneth R Cooke; Allen R Chen; Christopher J Gamper; Orly R Klein; Elias T Zambidis; Brandon Luber; Gary Rosner; Nicholas Siegel; Mary Jo Holuba; Nancy Robey; Masanori Hayashi; Richard J Jones; Ephraim Fuchs; Matthias Holdhoff; David M Loeb; Heather J Symons Journal: Biol Blood Marrow Transplant Date: 2017-08-12 Impact factor: 5.742
Authors: Gary K Schwartz; William D Tap; Li-Xuan Qin; Michael B Livingston; Samir D Undevia; Bartosz Chmielowski; Mark Agulnik; Scott M Schuetze; Damon R Reed; Scott H Okuno; Joseph A Ludwig; Vicki Keedy; Petra Rietschel; Andrew S Kraft; Douglas Adkins; Brian A Van Tine; Bruce Brockstein; Vincent Yim; Christiana Bitas; Abdul Abdullah; Cristina R Antonescu; Mercedes Condy; Mark A Dickson; Shyamprasad Deraje Vasudeva; Alan L Ho; L Austin Doyle; Helen X Chen; Robert G Maki Journal: Lancet Oncol Date: 2013-03-08 Impact factor: 41.316
Authors: Benjamin A Gartrell; Jian Ying; Shanthi Sivendran; Kenneth M Boucher; Toni K Choueiri; Guru Sonpavde; William K Oh; Neeraj Agarwal; Matthew D Galsky Journal: Target Oncol Date: 2013-07-13 Impact factor: 4.493
Authors: Don W Coulter; Christine Walko; Jai Patel; Billie M Moats-Staats; Andrew McFadden; Scott V Smith; Wasiuddin A Khan; Arlene S Bridges; Allison M Deal; Javier Oesterheld; Ian J Davis; Julie Blatt Journal: Anticancer Drugs Date: 2013-04 Impact factor: 2.248
Authors: Shanthi Sivendran; Neeraj Agarwal; Benjamin Gartrell; Jian Ying; Kenneth M Boucher; Toni K Choueiri; Guru Sonpavde; William K Oh; Matthew D Galsky Journal: Cancer Treat Rev Date: 2013-05-16 Impact factor: 12.111